Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 4/2018

Open Access 01-08-2018 | Original Article

A clinicopathological study of parotid carcinoma: 18-year review of 171 patients at a single institution

Authors: Akira Nishikado, Ryo Kawata, Shin-ichi Haginomori, Tetsuya Terada, Masaaki Higashino, Yoshitaka Kurisu, Yoshinobu Hirose

Published in: International Journal of Clinical Oncology | Issue 4/2018

Login to get access

Abstract

Background

This study investigated the clinical outcomes of patients with parotid carcinoma at a single institution during an 18-year period, with the focus on diagnosis, treatment, and survival.

Methods

The subjects were 171 patients with parotid carcinoma treated at our department during the 18-year period from September 1999 to August 2017. There were 19 patients in stage I, 65 patients in stage II, 22 patients in stage III, and 65 patients in stage IV. The symptoms, preoperative diagnosis, node metastasis, survival rate, prognostic factors, and immunohistological findings were investigated.

Results

Preoperative diagnosis of the histological grade by fine-needle aspiration cytology was only possible in 34% of the patients, while the histological grade was correctly determined by frozen section biopsy in 72%. The overall frequency of lymph node metastasis was 29%, with 59% in patients with high-grade carcinoma and only 6% in those with low-/intermediate-grade tumors. The disease-specific 5-year survival rate was 100% for patients in stage I, 95.2% in stage II, 70.4% in stage III, and 45.1% in stage IV. Multivariate analysis showed that the pathological grade was the most important prognostic factor. Immunohistological investigation showed patients with HER-2 or androgen receptor-positive tumors had a significantly worse prognosis.

Conclusions

Although a high-grade tumor is the most important prognostic factor, preoperative diagnosis of the grade was not always accurate. Since advanced cancer has a poor prognosis with a limited response to surgery and radiation therapy, development of new treatment strategies, such as molecular-targeting therapies directed against HER-2 and AR, is required.
Literature
1.
Cederblad L, Johansson S, Enblad G et al (2009) Cancer of the parotid gland; long-term follow-up. A single centre experience on recurrence and survival. Acta Oncol 148(4):549–555CrossRef
2.
Spitz MR, Batsakis JG (1984) Major salivary gland carcinoma. Descriptive epidemiology and survival of 498 patients. Arch Otolaryngol 110(1):45–49CrossRefPubMed
3.
El-Naggar AK, Chan JK, Grandis JR et al (2017) World Health Organization classification of tumours. Chapter 7, tumours of salivary glands. IARC press, Lyon, pp 160–202
4.
Schmidt RL, Hall BJ, Wilson AR et al (2011) A systematic review and meta-analysis of the diagnostic accuracy of fine-needle aspiration cytology for parotid gland lesions. Am J Clin Pathol 136(1):45–59CrossRefPubMed
5.
Colella G, Cannavale R, Flamminio F et al (2010) Fine-needle aspiration cytology of salivary gland lesions: a systematic review. J Oral Maxillofac Surg 68(9):2146–2153CrossRefPubMed
6.
Terhaard CH (2007) Postoperative and primary radiotherapy for salivary gland carcinomas: indications, techniques, and results. Int J Radiat Oncol Biol Phys 69(2):52–55CrossRef
7.
Noh JM, Ahn YC, Nam H et al (2010) Treatment results of major salivary gland cancer by surgery with or without postoperative radiation therapy. Clin Exp Otorhinolaryngol 3(2):96–101CrossRefPubMedPubMedCentral
8.
Richter SM, Friedmann P, Mourad WF et al (2011) Postoperative radiation therapy for small, low-/intermediate-grade parotid tumors with close and/or positive surgical margins. Head Neck 34(7):953–955CrossRefPubMed
9.
Williams MD, Roberts DB, Kies MS et al (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeuticsignificance. Clin Cancer Res 16:2266–2274CrossRefPubMedPubMedCentral
10.
Vidal L, Tsao MS, Pond GR et al (2009) Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck 31:1006–1012CrossRefPubMedPubMedCentral
11.
Dobashi Y, Suzuki S, Kimura M et al (2011) Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas. Hum Pathol 42:214–226CrossRefPubMed
12.
Suzuki S, Igarashi S, Hanawa M et al (2006) Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. Mod Pathol 19:986–998CrossRefPubMed
13.
Eveson JW, Auclair P, Gnepp DR et al (2005) Tumors of the salivary glands: introduction. In: Barnes L, Everson JW, Reichart PDS (eds) Pathology and genetics of head and neck tumors. WHO classification of tumors. IARC, Lyon
14.
Pohar S, Gay H, Rosenbaum P et al (2005) Malignant parotid tumors: presentation, clinical/pathologic prognostic factors, and treatment outcomes. Int J Radiat Oncol Biol Phys 61(1):112–118CrossRefPubMed
15.
Godballe C, Schultz JH, Krogdahl A et al (2003) Parotid carcinoma: impact of clinical factors on prognosis in a histologically revised series. Laryngoscope 113:1411–1417CrossRefPubMed
16.
Stodulski D, Mikaszewski B, Stankiewicz C (2012) Signs and symptoms of parotid gland carcinoma and their prognostic value. Int J Oral Maxillofac Surg 41(7):801–806CrossRefPubMed
17.
Spiro RH, Huvos AG, Strong EW (1975) Cancer of the parotid gland. A clinicopathologic study of 288 primary cases. Am J Surg 130(4):452–459CrossRefPubMed
18.
Frankenthaler RA, Luna MA, Lee SS et al (1991) Prognostic variables in parotid gland cancer. Arch Otolaryngol Head Neck Surg 117:1251–1256CrossRefPubMed
19.
Eneroth CM (1972) Facial nerve paralysis, a criterion of malignancy in parotid tumors. Arch Otolaryngol 95:300–304CrossRefPubMed
20.
Poorten VLMV, Balm AJM, Hilgers FJM et al (1999) The development of a prognostic score for patients with parotid carcinoma. Cancer 85:2057–2067CrossRef
21.
Santos IR, Kowalski LP, Araujo VC et al (2001) Multivariate analysis of risk factors for neck metastases in surgically treated parotid carcinomas. Arch Otolaryngol Head Neck Surg 127:56–60CrossRef
22.
Zbären P, Nuyens M, Loosli H et al (2004) Diagnostic accuracy of fine-needle aspiration cytology and frozen section in primary parotid carcinoma. Cancer 100(9):1876–1883CrossRefPubMed
23.
Seethala RR, LiVolsi VA, Baloch ZW (2005) Relative accuracy of fine-needle aspiration and frozen section in the diagnosis of lesions of the parotid gland. Head Neck 27(3):217–223CrossRefPubMed
24.
Alphs HH, Eisele DW, Westra WH (2006) The role of fine needle aspiration in the evaluation of parotid masses. Curr Opin Otolaryngol Head Neck Surg 14(2):62–66CrossRefPubMed
25.
Nishikawa S, Kawata R, Higashino M et al (2015) Assessing the histological type and grade of primary parotid carcinoma by fine-needle aspiration and frozen section. Auris Nasus Larynx 42(6):463–468CrossRefPubMed
26.
Medina JE (1998) Neck dissection in the treatment of cancer of major salivary glands. Otolaryngol Clin N Am 31:815–822CrossRef
27.
Armstrong JG, Harrison LB, Thaler HT et al (1992) The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer 69:615–619CrossRefPubMed
28.
Zbären P, Schüpbach J, Nuyens M, Stauffer E (2005) Elective neck dissection versus observation in primary parotid carcinoma. Otolaryngol Head Neck Surg 132:387–391CrossRefPubMed
29.
Klussmann JP, Ponert T, Mueller RP, Dienes HP, Guntinas Lichius O (2008) Patterns of lymph node spread and its influence on outcome in resectable parotid cancer. Eur J Surg Oncol 34:932–937CrossRefPubMed
30.
31.
Eneroth CM, Hamberger CA (1974) Principles of treatment of different types of parotid tumors. Laryngoscope 84:1732–1740CrossRefPubMed
32.
Hui KK, Batsakis JG, Luna MA, Mackay B, Byers M (1986) Salivary duct adenocarcinoma: a high grade malignancy. J Laryngol Otol 100(1):105–114CrossRefPubMed
33.
Yan M, Parker BA, Schwab R, Kurzrock R (2014) HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev 40(6):770–780CrossRefPubMed
34.
Glisson B, Colevas AD, Haddad R et al (2004) HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 10(3):944–946CrossRefPubMed
35.
Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Löning T (2005) Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 103(12):2526–2533CrossRefPubMed
36.
Hashimoto K, Yamamoto H, Shiratsuchi H et al (2012) HER-2/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in situ hybridization study. Histopathology 60:131–142CrossRef
37.
Locati LD, Perrone F, Losa M et al (2009) Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol 45:986–990CrossRefPubMed
38.
Keller G, Steinmann D, Quaas A et al (2017) New concepts of personalized therapy in salivary gland carcinomas. Oral Oncol 68:103–113CrossRefPubMed
39.
Prat A, Parera M, Reyes V et al (2008) Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 30(5):680–683CrossRefPubMed
40.
Nashed M, Casasola RJ (2009) Biological therapy of salivary duct carcinoma. J Laryngol Otol 123(2):250–252CrossRefPubMed
41.
Jaspers HC, Verbist BM, Schoffelen R et al (2011) Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 29(16):473–476CrossRef
Metadata
Title
A clinicopathological study of parotid carcinoma: 18-year review of 171 patients at a single institution
Authors
Akira Nishikado
Ryo Kawata
Shin-ichi Haginomori
Tetsuya Terada
Masaaki Higashino
Yoshitaka Kurisu
Yoshinobu Hirose
Publication date
01-08-2018
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-018-1266-7

Other articles of this Issue 4/2018

International Journal of Clinical Oncology 4/2018 Go to the issue

Original Article

Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer

Original Article

Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors

Original Article

The prognostic significance of surgical treatment for excessive elderly patients with soft tissue sarcoma

Original Article

Five-year outcomes following hypofractionated stereotactic radiotherapy delivered in five fractions for acoustic neuromas: the mean cochlear dose may impact hearing preservation

Original Article

Hibernation of masses suspected to be remnant tumors after surgical resection of retroperitoneal liposarcoma is related to improved overall survival

Original Article

Interleukin-1 receptor antagonist inhibits angiogenesis in gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits